Temple's Dr. Candrice Heath (Candrice Heath, MD) earns Robert A. Winn Diversity in Clinical Trials Career Development Award
Read more:
templehealth.org/about/news/dr-…

The TIGER trial has officially reached our target accrual! Thanks to all investigators, Alliance for Clinical Trials in Oncology, EORTC, ANZUP, Movember USA, and most of all to patients and their families. Uromigos Tom Powles silke gillessen Michael Morris, Robert Motzer MD Jonathan Rosenberg MD

🔶Neoadjuvant ddMVACx6 was more cost-effective 💵💶 than GCx4 for muscle-invasive bladder cancer.

🔶Do we need 6 or ddMVACx4 is enough?
ACS Journal Cancer Vidit Sharma Stephen Boorjian, MD Elizabeth Plimack MD Bladder Cancer Advocacy Network ASCO OncoAlert GETUG European Association of Urology (EAU)
doi.org/10.1002/cncr.3…

Let's Go!!

Fox Chase PA-C's Carolyn Zawislak, Victoria Wong, and retired NP Barbara Rogers received the 2021 Article of the Year award for their review article, “Management of Hematologic Adverse Events Associated With Immune Checkpoint Inhibitors' from JADPRO: bit.ly/3Slva2S

Looking forward to presenting at ESMO Philadelphia Conference! Leading cancer experts will share the most practice changing treatment data. Please join us for FREE in-person or virtually. 
📅 Oct. 22-23, 2022
Register Free:  bit.ly/3T6x0pk Total Health | Oncology 📖🔬

Laura Bukavina Neema Navai Kelly Bree MD Anderson Cancer Center Journal of Urology Andrea Kokorovic MD Mary Beth Westerman Patrick Hensley, MD Nate Brooks Ashish M. Kamat, MD, MBBS Joshua Meeks Elizabeth Plimack MD Matthew Zibelman Fern Anari delay
perf risk
costs
taxing on patients
taxing on OR schedules of busy services
potential other harms (eg ⬆️in CTC?)

burden of proof on this is on the advocates of T2 reresection

auajournals.org/doi/10.1016/j.…

pubmed.ncbi.nlm.nih.gov/33766464/#:~:t….

Proud of our work and newest faculty ⁦Kelly Bree⁩ for this practice informing study. ⁦MD Anderson Cancer Center⁩ ⁦Journal of Urology⁩ Andrea Kokorovic MD⁩ ⁦Mary Beth Westerman⁩ ⁦Patrick Hensley, MD⁩ ⁦Nate Brooks⁩ ⁦⁦Ashish M. Kamat, MD, MBBS⁩ ⁦Joshua Meeks⁩ auajournals.org/doi/10.1097/JU…

Fox Chase was recently awarded a grant for $6 million over the course of 5 years to develop a new Cancer Prevention-Interception Targeted Agent Discovery Program (CAP-IT). Margie Clapper, PhD, led the successful grant application. Read more: bit.ly/3TaCW0K

Brian Rini, MD Tom Powles IKCC Kidney Cancer Oncology Brothers Sumanta Pal Neeraj Agarwal Shilpa Gupta 𝐂𝐡𝐚𝐧𝐝𝐥𝐞𝐫 𝐏𝐚𝐫𝐤 𝐌𝐃 𝐅𝐀𝐂𝐏 Tom Jayram Moshe Ornstein MD Tian Zhang, MD, MHS While my actions appeared to be 'eyerolls', most, but not all, were likely unconscious maneuvers that occur when searching my brain for response to the Loquacios Londoner:ncbi.nlm.nih.gov/pmc/articles/P…

Congrats to our Chair, Dr. Kimryn Rathmell, on her election to National Academy of Medicine for “paving the way for new therapeutics” for basic science investigations of kidney cancer, and for the mentorship, recognition, and career advancement of physician-scientists.

bit.ly/3s8hEVD

Join Dr. Andres Correa (Andres Correa), Dr. Elias Obeid (@eiobeid), Dr. Fern Anari (@AnariFern) & other faculty at the 11/9 in person CME: Optimizing Treatment Strategies for Localized and Advanced Prostate Cancer. For more information and to register, visit: bit.ly/3eolA1m

Temple Health has been honored by the AMA for promoting the well-being of health care workers! We are 1 of 28 organizations recognized nationwide & the only hospital system in Philadelphia to earn this recognition! Read more here: bit.ly/3rYnKry

Comparison of real-world 1st-Line Ipi/Nivo or Axi/Pembro in Metastatic Clear Cell RCC
🔸Favorable risk: axi/pembro provides better outcomes
🔸Inter/poor risk: no difference
@KevinZarrabi Elizabeth Plimack MD The Oncologist OncoAlert #kidney #Cancer ASCO ESMO - Eur. Oncology
doi.org/10.1093/oncolo…